Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The number of patients with type 2 diabetes mellitus (DM2) and comorbid conditions is steadily increasing worldwide. For patients with DM2, achieving target carbohydrate metabolism parameters is important, as is weight loss, improving blood lipid profiles and blood pressure, and optimizing the course of comorbid conditions. The most commonly discussed comorbid conditions are lower extremity peripheral arterial disease (LEPAD), cardiovascular disease (CVD), metabolic-associated fatty liver disease (MAFLD), and diabetic kidney disease (DKD). Improved carbohydrate metabolism, weight loss, and reduced progression of cardiovascular disease, LEAD, MAFLD, and DKD can be achieved with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 agonist). Semaglutide has demonstrated high efficacy in correcting glycemic and lipid profiles, as well as reducing body weight and blood pressure. Multicenter clinical trials have demonstrated its pronounced cardio-nephro-hepatoprotective effects, as well as a significant reduction in the risk of developing and progressing micro- and macrovascular complications.

About the authors

O. M. Koteshkova

Endocrinology Dispensary of the Moscow Healthcare Department

Author for correspondence.
Email: koala58@mail.ru
ORCID iD: 0000-0001-8428-4116
SPIN-code: 6141-1224

Cand. Sci. (Med.), Head of the Diabetes Education and Treatment Department

Russian Federation, Moscow

D. M. Antsiferova

Endocrinology Dispensary of the Moscow Healthcare Department; Russian Medical Academy of Continuous Professional Education

Email: cifrenda@yandex.ru
ORCID iD: 0000-0002-3920-5914

Endocrinologist, Endocrinology Dispensary of the Moscow Healthcare Department; Postgraduate Student, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow; Moscow

M. B. Antsiferov

Endocrinology Dispensary of the Moscow Healthcare Department

Email: antsiferov@rambler.ru
ORCID iD: 0000-0002-9944-2997
SPIN-code: 1035-4773

Dr. Sci. (Med.), Professor, President

Russian Federation, Moscow

References

  1. IDF diabetes atlas / International Diabetes Federation. 11th Edition. Brussels, 2025. URL: https://diabetesatlas.org.
  2. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes – 2024. Diab Care. 2024;47(Suppl. 1):S179–218. https://dx.doi.org/10.2337/dc24-S010
  3. Анциферов М.Б., Котешкова О.М., Анциферова Д.М., Демидов Н.А. Агонисты рецепторов глюкагоноподобного пептида-1 в лечении сахарного диабета 2 типа: как выбрать правильное решение. Фарматека. 2023;30(12):116–26. https://dx.doi.org/10.18565/pharmateca.2023.12.116-126
  4. Barnes J.A., Eid M.A., Creager M.A., Goodney P.P. Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40(8):1808–17. https://doi.org/10.1161/ATVBAHA.120.314595
  5. Shah A.D., Langenberg C., Rapsomaniki E., et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1·9 million people. Lancet. Diab Endocrinol. 2015;385(2):S86. https://dx.doi.org/10.1016/S2213-8587(14)70219-0
  6. Bonaca M.P., Catarig A.M., Houlind K., et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 ;405(10489):1580–93. https://dx.doi.org/10.1016/S0140-6736(25)00509-4
  7. Marso S.P., Bain S.C., Consoli A., et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–44. https://dx.doi.org/10.1056/NEJMoa1607141
  8. Lee M.M.Y., Sattar N., Pop-Busui R., Deanfield J., et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diab Care. 2025;48(5):846–59. https://dx.doi.org/10.2337/dc25-0241
  9. Pharmacologic-Approaches-to-Glycemic-Treatment. Diab Care. 2025;48(Suppl._1):S181–206. https://doi.org/10.2337/dc25-S009
  10. Riazi K., Azhari H., Charette J.H., et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet. Gastroenterol Hepatol. 2022;7:851–61. https://dx.doi.org/10.1016/S2468-1253(22)00165-0
  11. Cheemerla S., Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken). 2021;17:365–70. https://dx.doi.org/10.1002/cld.1061
  12. Zhu K., Kakkar R., Chahal D., et al. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023;29(37):5327–38. https://dx.doi.org/10.3748/wjg.v29.i37.5327
  13. Estes C., Razavi H., Loomba R., et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33. https://dx.doi.org/10.1002/hep.29466
  14. Golabi P., Otgonsuren M., Cable R., et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016;14:18. https://dx.doi.org/10.1186/s12955-016-0420-z
  15. Younossi Z.M., Blissett D., Blissett R., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86. https://dx.doi.org/10.1002/hep.28785
  16. Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–73. Doi.org/10.1001/jama.2015.5370
  17. Caussy C., Vergès B., Leleu D., et al. Screening for metabolic dysfunction–associated steatotic liver disease–related advanced fibrosis in diabetology: a prospective multicenter study. Diab Care. 2025;48(6):877–86. https://dx.doi.org/10.2337/dc24-2075
  18. Singh J., Ibrahim B., Jackson N.J., et al. Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population. Transl Gastroenterol Hepatol. 2024;9:16. https://dx.doi.org/10.21037/tgh-23-62
  19. Martínez-Sánchez F.D., Corredor-Nassar M.J., Feria-Agudelo S.M., et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes: a multicentric study in Mexico City. J Clin Exp Hepatol. 2025 15(4):102536. https://dx.doi.org/10.1016/j.jceh.2025.102536
  20. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–21. [Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis based on diabetes registry data as of 01.01.2021. Diabetes mellitus. 2021;24(3):204–21. (In Russ.)]. https://dx.doi.org/10.14341/DM20213
  21. Errafii K., Khalifa O., S Al-Akl N., Arredouani A. Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid. Metab Biomed. 2022;10(5):1020. https://dx.doi.org/10.3390/biomedicines10051020
  22. Dichtel L.E. The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis. Hepatology. 2021;74:2290–2. https://dx.doi.org/10.1002/hep.31886
  23. Targher G., Mantovani A., Byrne C.D. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet. Gastroenterol Hepatol. 2023;8:179–91. https://dx.doi.org/10.1016/S2468-1253(22)00338-7
  24. Nauck M.A., Meier J.J. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–34. https://dx.doi.org/10.1530/EJE-19-0566
  25. Wilding J.P.H., Batterham R.L., Calanna S., et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. https://dx.doi.org/10.1056/NEJMoa2032183
  26. Loomba R., Abdelmalek M.F., Armstrong M.J., et al.; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet. Gastroenterol Hepatol. 2023;8:511–22. https://dx.doi.org/10.1016/S2468-1253(23)00068-7
  27. Loomba R., Sanyal A.J., Kowdley K.V., et al. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019;156:88–95.e5. https://dx.doi.org/10.1053/j.gastro.2018.09.021
  28. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367–78.e5; quiz e14. https://dx.doi.org/10.1053/j.gastro.2015.04.005
  29. Cusi K., Abdelmalek F.M., Apovian C.M., et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diab Care. 2025;48:1057–82. https://dx.doi.org/https://doi.org/10.2337/dci24-0094
  30. Котешкова О.М., Анциферова Д.М., Голубева Ю.В. и др. Эффективность и безопасность российского агониста рецепторов глюкагоноподобного пептида-1 Семавик (семаглутид) у пациентов с сахарным диабетом 2 типа. Клинические наблюдения из практики эндокринолога. Лечебное дело. 2024;4:44–53. [Koteshkova O.M., Antsiferova D.M., Golubeva Yu.V., et al. Efficacy and safety of the Russian glucagon-like peptide-1 receptor agonist Semavic (semaglutide) in patients with type 2 diabetes mellitus. Clinical observations from an endocrinologist’s practice. Lechebnoe delo. 2024;4:44–53. (In Russ.)].
  31. Ndumele C.E., Neeland I.J., Tuttle K.R., et al.; American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 2023;148:1636–64. https://dx.doi.org/10.1161/CIR.0000000000001186
  32. Grams M.E., Coresh J., Matsushita K., et al.; Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330:1266–77. https://dx.doi.org/10.1001/jama.2023.17002
  33. Blazek O., Bakris G.L. Slowing the progression of diabetic kidney disease. Cells. 2023;12:1975. https://dx.doi.org/10.3390/cells12151975
  34. de Boer I.H., Khunti K., Sadusky T., et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102:974–89. https://dx.doi.org/10.2337/dci22-0027
  35. Perkovic V., Tuttle K.R., Rossing P., et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–21. https://dx.doi.org/10.1056/NEJMoa2403347
  36. Yang Q., Lang Y., Yang W., et al. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023;198:110592. https://dx.doi.org/10.1016/j.diabres.2023.110592
  37. Rossing P., Baeres F.M.M., Bakris G., et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38:2041–51. https://dx.doi.org/10.1093/ndt/gfad009
  38. Rossing P., Bakris G., Perkovic V., et al.; FLOW Investigator Group. Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. Diab Care. 2025;48:1878–87. https://dx.doi.org/10.2337/dc25-0472
  39. Agarwal R., Kolkhof P., Bakris G., et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–61. https://dx.doi.org/10.1093/eurheartj/ehaa736

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).